Mackay Shields LLC’s DexCom DXCM Stock Holding History

Mackay Shields LLC’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-55,852	Closed	-$7.14M	–	382
2022 Q1	$7.14M	Sell	55,852 -2,188	-4%	-$239K	0.06%	277
2021 Q4	$7.79M	Sell	58,040 -1,256	-2%	-$180K	0.06%	270
2021 Q3	$8.11M	Sell	59,296 -1,712	-3%	-$216K	0.08%	238
2021 Q2	$6.51M	Sell	61,008 -2,968	-5%	-$285K	0.06%	279
2021 Q1	$5.75M	Sell	63,976 -448	-0.7%	-$42.1K	0.04%	442
2020 Q4	$5.96M	Sell	64,424 -744	-1%	-$66.4K	0.04%	442
2020 Q3	$6.72M	Sell	65,168 -28,056	-30%	-$2.93M	0.05%	401
2020 Q2	$9.45M	Buy	93,224 +78,608	+538%	+$7.03M	0.08%	291
2020 Q1	$984K	Buy	+14,616	New	+$910K	0.01%	949
2019 Q2	–	Sell	-10,576	Closed	-$315K	–	1425
2019 Q1	$315K	Sell	10,576 -112,688	-91%	-$3.96M	﹤0.01%	1267
2018 Q4	$3.69M	Buy	+123,264	New	+$3.91M	0.03%	538

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mackay Shields LLC's DXCM Position: Q2 2022 in Review

Mackay Shields LLC sold out of DexCom (DXCM) in Q2 2022, closing a stake of 55,852 shares — an estimated $7.14M sold.

Mackay Shields LLC first reported a position in DXCM in Q4 2018 and held it in 11 quarters. The position peaked at $9.45M in Q2 2020. 798 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

Mackay Shields LLC reported no remaining DexCom position as of Q2 2022 after selling out during the quarter.
Mackay Shields LLC sold 55,852 DexCom shares in Q2 2022, an estimated $7.14M.
Mackay Shields LLC first reported a position in DexCom in Q4 2018 and held it in 11 quarters.
Mackay Shields LLC's DexCom position peaked at $9.45M in Q2 2020.
798 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on Mackay Shields LLC's 13F filing for Q2 2022, filed 3 Aug 2022.